Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094958 | 0.79 | HRH4 (0.39) | HRH4PTGDR2PTGDRIRAK4CDC7 | |
| SCHEMBL3081871 | 0.78 | IRAK4 (0.40) | PTGDR2PTGDRIRAK4RET | |
| SCHEMBL4153906 | 0.77 | SCN10A (0.40) | HRH4PTGDR2CDC7 | |
| SCHEMBL9207313 | 0.76 | MAPT (0.40) | HRH4PTGDR2PTGDRCDC7 | |
| SCHEMBL9207129 | 0.76 | MAPT (0.40) | HRH4PTGDR2PTGDRCDC7 | |
| SCHEMBL7511256 | 0.74 | MAPT (0.41) | HRH4PTGDR2CDC7 | |
| SCHEMBL3094967 | 0.69 | RET (0.37) | HRH4IRAK4CYP19A1CDC7RET | |
| SCHEMBL9206473 | 0.68 | CNR1 (0.36) | HRH4RET | |
| SCHEMBL29289787 | 0.67 | MAPT (0.40) | HRH4PTGDR2CDC7 | |
| SCHEMBL31668887 | 0.67 | HTT (0.43) | HRH4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HRH4 93/4885PTGDR2 1729/4885PTGDR 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.